OpenRounds Editorial
Daily Briefing
Tuesday, June 23, 2026
What Changed
Characterising 'Watch and Wait' prescribing patterns in paediatric otitis media using large language models and pharmacy dispense data (BMJ health & care informatics) sets the agenda today, with OpenAI’s Karan Singal on HealthBench and the Future of Medical AI (NEJM Group) reinforcing the same shift toward decisions healthcare AI leaders may need to track now [1][2].
Research
•[AI Evidence] Characterising 'Watch and Wait' prescribing patterns in paediatric otitis media using large language models and pharmacy dispense data (BMJ health & care informatics) [1]. It helps operators separate early technical promise from evidence that could eventually influence workflow, validation, or procurement decisions. The evidence still needs broader validation or real-world implementation proof before it should change care delivery.
•[AI Evidence] OpenAI’s Karan Singal on HealthBench and the Future of Medical AI (NEJM Group) [2]. It helps operators separate early technical promise from evidence that could eventually influence workflow, validation, or procurement decisions. The evidence still needs broader validation or real-world implementation proof before it should change care delivery.
•[AI Evidence] Comparison of Large Language Model-Based Systems and Prompt Engineering for Internal Medicine Clinical Pharmacy Cases (Journal of the American College of Clinical Pharmacy : JACCP) [3]. It helps operators separate early technical promise from evidence that could eventually influence workflow, validation, or procurement decisions. The evidence still needs broader validation or real-world implementation proof before it should change care delivery.
•[AI Evidence] Solidarity or Segregation? ChatGPT Health and US Health Care Disparities (JMIR) [4]. It helps operators separate early technical promise from evidence that could eventually influence workflow, validation, or procurement decisions. The evidence still needs broader validation or real-world implementation proof before it should change care delivery.
•[AI Evidence] RAISE Health Symposium 2026 Highlights (Stanford Medicine) [5]. It helps operators separate early technical promise from evidence that could eventually influence workflow, validation, or procurement decisions. The evidence still needs broader validation or real-world implementation proof before it should change care delivery.
•[AI in Biopharma] New AI-powered platform helps researchers find promising cancer therapies faster (UCLA Health Newsroom) [6]. It helps operators separate early technical promise from evidence that could eventually influence workflow, validation, or procurement decisions. The evidence still needs broader validation or real-world implementation proof before it should change care delivery.